Aducanumab (Mouse IGG2a) 

Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research^[1].

Aducanumab (Mouse IGG2a) (0.31-40 μM, 2 min) has extremely weak monovalent binding, with a K_D of ~9 μM for its Fab for surface-captured monomeric Aβ_1-40-biotin^[1].
Aducanumab (Mouse IGG2a) (5 μM) shows very weak affinity with Aβ peptide with K_Ds of 1.8  and 5.9 μM for Aβ_1-16 and Aβ_1-28 peptide^[1].
Aducanumab (Mouse IGG2a) had weak affinity with imeric and tetrameric multi-antigen peptides (MAPs) with EC₅₀s of > 1 μM and ~7 nM for dimeric and tetrameric Aβ_1-15 MAP, respectively^[1].
Aducanumab (Mouse IGG2a) efficiently binds the immobilized Aβ in a surplus of free monomer with IC₅₀ of >1 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

[Aducanumab (Mouse IGG2a)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Arndt JW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018 Apr 23;8(1):6412.  [Content Brief]